Doxorubicin nanoparticles - Onxeo

Drug Profile

Doxorubicin nanoparticles - Onxeo

Alternative Names: BA-003; Doxorubicin Transdrug; Doxorubicin-Transdrug; Livatag

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator BioAlliance Pharma
  • Developer CNRS; Onxeo SA
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Hepatocellular carcinoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Preclinical Pancreatic cancer
  • Discontinued Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 25 Jan 2017 Onxeo completes enrolment in its phase III trial for Hepatocellular carcinoma in USA, France, Spain, Belgium, Hungary, Austria, Italy, Egypt, Lebanon, Russia, Saudi Arabia, Turkey and Germany
  • 04 Nov 2016 Preclinical trials in Pancreatic cancer in France
  • 03 Nov 2016 9205773 - KDM updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top